Modified-IgG Antibodies Enhance TGFβ1 Binding Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies that target TGFβ1 often lack the necessary affinity and specificity to effectively neutralize TGFβ1 while avoiding binding to TGFβ2 and TGFβ3, which are important for vascular development and immune cell function.
Innovation Solution
Development of modified-IgG antibodies with enhanced affinity and specificity for TGFβ1 by modifying the VH and VL domains of existing antibodies like metelimumab, incorporating additional amino acids in the elbow regions to improve flexibility and binding capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If pan-specific TGFβ antibodies (e.g., GC1008) are used to neutralize all three TGFβ isoforms, then broad coverage is achieved, but specificity for TGFβ1 is lost and binding to TGFβ2/TGFβ3 occurs
Solution Approach 1:
The patent applies local quality by modifying specific regions (elbow regions) of the antibody structure to create localized differences in binding characteristics. The modified-IgG antibodies have altered elbow regions that confer TGFβ1-specific binding while maintaining the overall antibody structure, thereby achieving high specificity without sacrificing the versatility of the antibody framework.
Solution Approach 2:
The patent employs parameter changes by introducing additional amino acids in the elbow regions, which alters the biophysical parameters of the antibody-antigen interaction. These parameter changes (additional amino acid residues) modify the binding affinity and specificity to achieve selective binding to TGFβ1 over TGFβ2 and TGFβ3.
2Reliability
If existing TGFβ1 antibodies (e.g., metelimumab) are used, then TGFβ1 binding is achieved, but affinity and neutralization capacity are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the elbow regions of the antibody to introduce additional amino acids that enhance the binding affinity. These structural modifications change the physical-chemical parameters of the antibody, resulting in modified-IgG antibodies with higher affinity and neutralization capacity for TGFβ1 compared to the parent metelimumab antibody.
Solution Approach 2:
The patent uses composite materials by combining the existing antibody framework with newly introduced amino acid sequences in the elbow regions. This composite structure integrates the functional framework of metelimumab with enhanced binding elements, creating an antibody molecule that possesses both the original binding capability and improved affinity.
3Manufacturing precision
If antibody structure is modified to improve TGFβ1 binding, then affinity increases, but structural complexity increases
Solution Approach 1:
The patent applies local quality by concentrating the structural modifications specifically in the elbow regions rather than altering the entire antibody structure. This localized modification approach improves affinity while minimizing the increase in overall structural complexity, as only specific segments of the antibody molecule are modified.
Solution Approach 2:
The patent employs parameter changes by introducing a limited number of additional amino acids (up to 5) in the elbow regions, which alters the binding parameters without proportionally increasing structural complexity. This controlled parameter modification achieves affinity enhancement with minimal impact on overall molecular complexity.
Data Source
AI summary
A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.